Denali Therapeutics
DNLI
202 hedge funds and large institutions have $2.49B invested in Denali Therapeutics in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 91 increasing their positions, 51 reducing their positions, and 21 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 51
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
3% more funds holding
Funds holding: 197 → 202 (+5)
1.47% more ownership
Funds ownership: 77.56% → 79.04% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
15% less capital invested
Capital invested by funds: $2.93B → $2.49B (-$441M)
91% less call options, than puts
Call options by funds: $999K | Put options by funds: $11.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.9M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$13.9M |
| 3 |
Temasek Holdings
Singapore
|
+$10.5M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.73M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.8M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$30.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$16.8M |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$12.4M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7M |
DNLI Hedge Fund Activity: Q1 2023 in Review
202 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2023, worth a combined $2.49B — down 15% from $2.93B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new DNLI positions and 21 closed out — a net gain of 6 holders — while 91 added to existing stakes and 51 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $36.9M. The largest seller was Fidelity Investments, cutting an estimated $30.8M.
- 202 institutional investors held Denali Therapeutics (DNLI) as of Q1 2023, up from 197 in Q4 2022.
- Funds reported $2.49B of Denali Therapeutics stock for Q1 2023, down 15% quarter-over-quarter.
- 27 funds opened new Denali Therapeutics positions in Q1 2023 and 21 closed out, a net change of +6 holders.
- The largest Denali Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $36.9M added.
- The largest Denali Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $30.8M sold.
Based on aggregated 13F filings for Q1 2023.